Traduction de «europe since the late 2007 launch » (Néerlandais → Français) :

Exelon/Exelon Patch (USD 436 million, +24% lc), a therapy for mild to moderate forms of Alzheimer’s disease dementia and also dementia linked with Parkinson’s disease, has seen dynamic growth in the US and Europe since the late 2007 launch of Exelon Patch, a novel skin patch, that accounts for about half of franchise net sales.
Exelon/Exelon Patch (USD 436 millions, +24% en m. l.), traitement des formes légères à modérées de la maladie d'Alzheimer et de la démence associée à la maladie de Parkinson, a affiché une forte croissance aux Etats-Unis et en Europe depuis le lancement, à fin 2007, d’Exelon Patch, une nouvelle formulation de patch transdermique, qui compte pour environ la moitié du chiffre d’affaires net de ce secteur d’activité.

Extavia (USD 12 million), for patients with some forms of multiple sclerosis (MS), has been prescribed for use by about 3,000 patients in Europe since the early 2009 launch that marks the entry of Novartis into this disease area.
Extavia (USD 12 millions), pour les malades atteints de certaines formes de sclérose en plaques (SEP), a été prescrit à quelque 3000 malades en Europe depuis son lancement début 2009 qui marque l’entrée de Novartis dans ce domaine thérapeutique.

Lucentis (USD 886 million, +122% lc), a biotechnology eye therapy now approved in more than 70 countries, has delivered dynamic growth since its first European launch in early 2007.
Lucentis (USD 886 millions, +122% en m. l.), traitement oculaire biotechnologique disponible dans plus de 70 pays, a connu une croissance vigoureuse depuis son premier lancement en Europe début 2007.

The number of early phase trials is per capita one of the highest in Europe. Since the publication of the guideline trials for conducting explorative studies in Belgium, in mid June 2007, 25 applications for conducting these clinical trials have been submitted to the FAMHP.
The number of early phase trials is per capita one of the highest in Europe. Since the publication of the guideline trials for conducting explorative studies in Belgium, in mid June 2007, 25 applications for conducting these clinical trials have been submitted to the FAMHP.

Forward, the Group-wide initiative launched in late 2007 to simplify structures and redesign the way Novartis operates, has been completed a year ahead of schedule after progressing rapidly and achieving more than USD 2.3 billion of cumulative cost savings since 2007 and exceeding its 2010 goal of USD 1.6 billion.
Les économies de coûts cumulées depuis 2007 se montent à plus d’USD 2,3 milliards, dépassant l’objectif d’USD 1,6 milliard en 2010.

Exforge (USD 406 million), a single-pill combination of the angiotensin receptor blocker Diovan (valsartan) with the calcium channel blocker amlodipine, has set new standards since its launch in late 2007 for the introduction of a high blood pressure combination therapy.
Exforge (USD 406 millions), une seule pilule associant Diovan (valsartan), un inhibiteur des récepteurs de l’angiotensine et l’amlodipine, inhibiteur des canaux calciques, a créé, depuis son lancement à fin 2007, de nouvelles normes en ce qui concerne le traitement combiné contre l’hypertension.

Aclasta/Reclast (USD 254 million), the first once-yearly infusion therapy for various forms of osteoporosis, has now been used in more than 350,000 patients and has experienced consistent growth since its launch to treat postmenopausal osteoporosis in late 2007.
Aclasta/Reclast (USD 254 millions), première injection annuelle pour soigner différentes formes d’ostéoporose, a été utilisé par plus de 350 000 patients et a affiché une croissance notable depuis son lancement, à fin 2007, pour le traitement de l’ostéoporose potsménopausique.

Responsibility for these issues used to lie with just one inspector. Since late 2007, however, four additional employees have been active in this investigation unit, since it is clear that this area requires a specialised approach.
Responsibility for these issues used to lie with just one inspector. Since late 2007, however, four additional employees have been active in this investigation unit, since it is clear that this area requires a specialised approach.

Onbrez Breezhaler (USD 5 million) has demonstrated strong performance following EU approval and since first launching in late 2009 in Germany for adult patients with chronic obstructive pulmonary disease (COPD).
Onbrez Breezhaler (USD 5 millions) a réalisé une excellente performance à la suite de son homologation dans l’UE et depuis son premier lancement à fin 2009 en Allemagne pour le traitement des adultes souffrant de broncho-pneumopathie chronique obstructive (BPCO).